WTI peptide vaccination for patients with high risk hematological malignancies.

Trial Profile

WTI peptide vaccination for patients with high risk hematological malignancies.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2010

At a glance

  • Drugs INNO 305 (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Dec 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Actual patient number (4) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top